
Taking Weekends Off Dasatinib Maintains Responses in First-Line CML
Key Takeaways
- A 5-days-on/2-days-off dasatinib regimen achieved noninferior 24-month MMR versus continuous dosing (78% vs 81%) using a prespecified 15% margin.
- First-line patients had comparable MMR with continuous and intermittent schedules, whereas later-line patients showed lower MMR with intermittent dosing, although subgroup analyses were exploratory.
The phase 3 DasaHIT trial found that weekend dasatinib breaks maintained CML responses in first-line patients, with fewer effusions in exploratory analyses.
An intermittent dasatinib (Sprycel) dosing schedule that allows patients with chronic-phase chronic myeloid leukemia (CML) to take weekends off treatment maintained major molecular response (MMR) rates compared with continuous daily dosing in the phase 3 DasaHIT trial (NCT02890784). Findings published in the Journal of Clinical Oncology demonstrated noninferior molecular responses at 24 months, although the intermittent schedule did not significantly improve the primary toxicity end point.¹
The results suggest that a 5-day treatment schedule may offer an alternative approach to managing long-term dasatinib therapy, particularly for patients receiving the agent as first-line treatment.
Weekend Dasatinib Dosing Maintains Molecular Responses
DasaHIT was a prospective, multicenter, randomized, open-label phase 3 trial evaluating whether intermittent dasatinib administration could maintain treatment efficacy while improving tolerability in patients with chronic-phase CML.2 Investigators randomly assigned 289 eligible patients to receive either continuous dasatinib at 100 mg once daily (n = 147) or intermittent treatment consisting of 100 mg once daily for 5 consecutive weekdays, followed by a 2-day treatment interruption over the weekend (n = 142).¹
Approximately 80% of participants (n = 232) received dasatinib as first-line treatment, while 57 patients received the agent in the second or later lines. The coprimary end points were MMR at 24 months and cumulative toxicity score during the first 24 months of treatment.
Among 260 patients, 206 (79%; 95% CI, 74%-84%) achieved MMR at 24 months. Rates were 81% (95% CI, 74%-88%) with continuous dosing and 78% (95% CI, 71%-85%) with intermittent dosing. Although the 3-percentage-point difference favored continuous treatment, intermittent dosing met the prespecified noninferiority criterion, with a 15% margin (P = .009).1
MMR rates at 24 months were comparable among patients receiving first-line dasatinib, at 79% with continuous dosing and 81% with intermittent dosing, meeting the noninferiority criterion. Among patients receiving second-line or later treatment, rates were 87% and 62.5%, respectively (P = .039), and noninferiority was not established. Investigators emphasized that these subgroup analyses were not prespecified and should be considered exploratory.
Weekend Dasatinib Breaks May Reduce Fluid-Related Toxicities
Although intermittent dosing maintained molecular responses, it did not demonstrate superiority for the primary toxicity end point. Grade 2 to 4 adverse events occurred in 58% of patients receiving continuous dasatinib and 56% receiving intermittent treatment. Median cumulative toxicity scores were also comparable between groups (2 in both arms; P = .83).¹
However, an exploratory post hoc analysis identified differences in pleural and pericardial effusions, known
Health-related quality of life (HRQOL) also favored intermittent dosing. Among 217 patients with evaluable questionnaires, clinically meaningful improvements were observed predominantly in patients receiving dasatinib as first-line treatment, whereas patients receiving later-line therapy experienced symptom deterioration. Overall HRQOL outcomes favored the intermittent schedule.
Longer Follow-Up Shows Favorable Survival Outcomes in CML
At a median follow-up of 43 months, no patients in either treatment group experienced progression to accelerated or blast phase CML, and no CML-related deaths were reported. Overall survival (OS) was 98% at 2 years (95% CI, 95%-99%) and 97% at 5 years (95% CI, 93%-98%). No statistically significant difference in OS was observed between treatment groups (P = .16).¹
The investigators noted that treatment tolerability and HRQOL remain important considerations as patients with CML increasingly achieve long-term disease control with tyrosine kinase inhibitors (TKIs). Distinguishing
In their conclusion, LaRosée et al stated that intermittent dasatinib dosing achieved "noninferior molecular efficacy with favorable effects on HRQOL and selected toxicities."
REFERENCES
La Rosée P, Ernst P, Fabisch C, et al. Dasatinib dose optimization with weekend drug holiday for improved tolerability in chronic myeloid leukemia (DasaHIT): a German Chronic Myeloid Leukemia Alliance randomized trial. J Clin Oncol. Published online November 13, 2026. doi:10.1200/JCO-26-00899
Dasatinib holiday for improved tolerability (DasaHIT). ClinicalTrials.gov. Updated May 10, 2023. Accessed November 20, 2026. https://clinicaltrials.gov/study/NCT02890784
Related to this article








